about
A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR EffectImmunotherapy for solid tumors--a review for surgeons.Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma.Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cellsCancer immunotherapy in clinical practice -- the past, present, and future.Cytokines and anti-cytokine therapy: clinical potential for treatment of feline disease.Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.Immunotherapy in acute myeloid leukemia.An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.Retroviral vector-mediated cytokine-gene transfer into tumor cells.Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.The biological therapy of acute and chronic leukemia.Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment.The isolation and sequence of canine interleukin-2.Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.
P2860
Q27300754-BAD0BAB6-3CAC-4EFB-9DE0-657479BFF5E0Q33709232-D51190F6-D3A6-4757-B6B5-12DBAE4C9FBAQ33827463-DC0A2430-969C-497B-B30E-16AA24CE9506Q34186892-DD32422B-5188-46D9-A511-20A45F5EC491Q34309399-472F27D9-092D-4461-8B62-919A98710EABQ34579927-8A9F04DF-1AAF-4C0F-B5EB-36F35582F291Q36470734-E3040727-745E-4C59-933B-D85C5DDB3954Q37065888-E1EE7AB9-C1E5-46C1-931E-F84DF2CACACEQ38533606-43032A5F-7D01-4F8C-AA5F-C6D00A7F0634Q40894584-0A9FFFFA-149E-4E0E-99E6-16DFB68076CDQ40903182-BA5058EC-79AD-4912-8885-9BEE40C79062Q40963463-BE8A0C73-3BDD-47CE-B360-460F80BCF28FQ41552414-95A10521-2B8D-4937-9FDF-EC37B9EE28DAQ45722362-CDCB26C2-BCA1-4194-807C-835DA1D57DA5Q45870075-A1FE0DCD-5F70-4824-8E90-627D747B4789Q48076600-6C8B47A1-E947-4E12-9956-A9E490A91ACFQ53751118-48B9C757-5075-44E6-B94B-147E35C8B358
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
IL2 treatment for cancer: from biology to gene therapy
@ast
IL2 treatment for cancer: from biology to gene therapy
@en
type
label
IL2 treatment for cancer: from biology to gene therapy
@ast
IL2 treatment for cancer: from biology to gene therapy
@en
prefLabel
IL2 treatment for cancer: from biology to gene therapy
@ast
IL2 treatment for cancer: from biology to gene therapy
@en
P2093
P2860
P921
P356
P1476
IL2 treatment for cancer: from biology to gene therapy
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1992.400
P407
P577
1992-12-01T00:00:00Z
P5875
P6179
1014597286